Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT006-AngQb in Mild to Moderate Essential Hypertension
NCT00710372Phase 2Completed
- Sponsor
- Cytos Biotechnology AG
- Start
- Jun 2008
- Primary completion
- Jul 2009
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of CYT006-AngQb in essential hypertension, sponsored by Cytos Biotechnology AG. Started Jun 2008; status: completed.
02
Drugs
CYT006-AngQb
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00710372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00710372.